PhRMA’s Vision For 21st Century Marketing Would Reshape Supplemental NDAs
Executive Summary
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.